Nektar's proprietary Advanced Polymer Conjugate Technology platform allows for a custom approach that capitalizes on the properties of polymer medicinal chemistry and an understanding of both a drug's characteristics and the body's mechanisms.
Our scientists identify specific drug molecules, both large and small, that with customized chemical modification using uniquely-designed polymers can be enabled or made more efficacious. With our proprietary conjugate approaches, suboptimal drugs can be designed to dial in desired therapeutic properties and create an optimized and potentially superior therapeutic.
Read about our advanced polymer conjugate technology approaches »
2008 Review Article in Journal of Pharmaceutical Sciences
| Aug. 5-7, 2011 |
Tenth International Congress on the Future of Breast Cancer |
Coronado, CA |
| Sep. 7-10, 2011 |
Pain Week 2011 |
Las Vegas, NV |
| Sep. 8-10, 2011 |
2011 ASCO Breast Cancer Symposium |
San Francisco, CA |
| Sep. 15-18, 2011 |
2nd AACR International Conference: Frontiers in Basic Cancer Research |
San Francisco, CA |
| Sep. 15-17, 2011 |
ISGIO 2011 Gastrointestinal Oncology Conference |
Philadelphia, PA |
| Sep. 20-23, 2011 |
AAPM Annual Clinical Meeting |
Las Vegas, NV |
| Sep. 20-21, 2011 |
Arrowhead’s 5th Annual Pain Therapeutics Summit |
San Francisco, CA |
| Sep. 23-27, 2011 |
16th ECCO - 36th ESMO Multidisciplinary Cancer Congress |
Stockholm, Sweden |
| Oct. 15-19, 2011 |
American Society of Anesthesiologists Annual Meeting |
Chicago, IL |
| Nov. 8-13, 2011 |
Chemotherapy Foundation Symposium |
New York, NY |
| Nov. 12-16, 2011 |
Society for Neuroscience: Neuroscience 2011 |
Washington, DC |
| Nov. 12-16, 2011 |
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics |
San Francisco, CA |
| Dec. 6-10, 2011 |
34th Annual CTRC-AACR San Antonio Breast Cancer Symposium |
San Antonio, TX |
|
 |
"When we design a new drug candidate, we bring together our knowledge of a drug with our understanding of medicinal polymer chemistry and the body's mechanisms. This allows us to turn a sub-optimal drug into a new chemical entity with the potential to be more efficacious and have more desirable characteristics."
Timothy A. Riley, Ph.D.
Senior Vice President, Global Research
|
